Literature DB >> 8616833

Lack of tumorigenicity of cholesterol epoxides and estrone-3,4-quinone in the rat mammary gland.

K el-Bayoumy1, B Y Ji, P Upadhyaya, Y H Chae, C Kurtzke, A Rivenson, B S Reddy, S Amin, S S Hecht.   

Abstract

The purpose of this study is to test the long-standing hypothesis that endogenous agents found in human breast fluid and in plasma are potential initiators of breast cancer. Therefore, we evaluated the tumorigenicity in the mammary glands of female CD rats of cholestan-5 alpha,6 alpha-epoxy-3 beta-ol (cholesterol-alpha-epoxide), cholestan-5 beta,6 beta-epoxy-3 beta-ol (cholesterol-beta-epoxide), and 1,5(10)estradiene-3,14,17-trione (estrone-3,4-quinone). As a positive control, trans-3,4-dihydroxy-anti-1,2-epoxy-1,2,3,4-tetrahydrobenzo[c]phenanthren e (BcPDE) was used. Rats were fed a high-fat AIN-76A diet (23.5% corn oil) to mimic the Western dietary composition. Because literature data suggest that the endogenous agents tested in this study are weak electrophiles, the total doses of cholesterol epoxides (12.3 mumol/rat) and of estrone-3,4-quinone (30 mumol/rat)were 10- and 25- fold higher, respectively, than that of BcPDE (1.2 mumol/rat). Each agent was dissolved in DMSO, and one-sixth of the total dose was injected under each of six nipples on the right side. The thoracic glands of the rat were treated at 30 days of age, and those located in the inguinal area were treated on the following day. The experiment was terminated at 44 weeks after treatment. Consistent with our previous study, BcPDE was a strong mammary carcinogen. However, there were no differences between rats treated with DMSO alone or those receiving DMSO containing cholesterol-alpha-epoxide, cholesterol-beta-epoxide, or estrone-3,4-quinone. The results of this study clearly indicate, for the first time, that metabolites derived from cholesterol and estrone lack tumorigenic activity in the rat mammary gland, at least under the conditions of the present protocol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8616833

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles.

Authors:  Michael R Paillasse; Nathalie Saffon; Heinz Gornitzka; Sandrine Silvente-Poirot; Marc Poirot; Philippe de Medina
Journal:  J Lipid Res       Date:  2012-01-29       Impact factor: 5.922

2.  Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands.

Authors:  Philippe de Medina; Michael R Paillasse; Gregory Segala; Marc Poirot; Sandrine Silvente-Poirot
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 3.  Induced mammary cancer in rat models: pathogenesis, genetics, and relevance to female breast cancer.

Authors:  James L Miller; Arianna P Bartlett; Rebecca M Harman; Prabin Dhangada Majhi; D Joseph Jerry; Gerlinde R Van de Walle
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-07-29       Impact factor: 2.698

4.  Dietary clofibrate stimulates the formation and size of estradiol-induced breast tumors in female August-Copenhagen Irish (ACI) rats.

Authors:  Sonia Mesia-Vela; Rosa I Sanchez; Kathleen G Roberts; Kenneth R Reuhl; Allan H Conney; Frederick C Kauffman
Journal:  Toxicology       Date:  2008-01-06       Impact factor: 4.221

Review 5.  Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention.

Authors:  James D Shull; Kirsten L Dennison; Aaron C Chack; Amy Trentham-Dietz
Journal:  Physiol Genomics       Date:  2018-01-26       Impact factor: 3.107

Review 6.  Potential mechanisms of estrogen quinone carcinogenesis.

Authors:  Judy L Bolton; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2007-12-04       Impact factor: 3.739

Review 7.  Mapping Mammary Tumor Traits in the Rat.

Authors:  Michael J Flister; Amit Joshi; Carmen Bergom; Hallgeir Rui
Journal:  Methods Mol Biol       Date:  2019
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.